San Diego CRO ChemDiv has signed up to a new drug discovery collab with Cystic Fibrosis Foundation Therapeutics (CFFT) to try to find new treatments for a disease with few drug options.
The agreement will see CFFT use ChemDiv's chemistry platform to advance promising scientific research in the field of cystic fibrosis (CF) treatment. The deal also allows ChemDiv to assist the largest CF clinical trials network in the world, and contribute to the development of a lifelong cure for cystic fibrosis.
Cystic fibrosis is the most common autosomal disease, threatening the lives of its victims due to its progressive destruction of lungs.
Patients frequently succumb to persistent lung infections as children or young adults. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with the disease worldwide and around 1,000 new cases of CF are diagnosed in the U.S. alone each year.
ChemDiv works as a CRO but also has its own library of molecules, with a commercial collection of more than 1.6 million lead-like and drug-like small molecules, the company said in a statement.
According to the agreement, ChemDiv will provide discovery chemistry services to CFFT for their new research programs aimed at the development of lifesaving new therapies for cystic fibrosis.
"ChemDiv's unique drug discovery and evaluation platforms will provide CFFT with an excellent jumpstart for the identification of multiple novel therapeutic targets," said Nikolay Savchuk, CEO of ChemDiv.
"We are proud to be a part of CFFT's exceptional research and development efforts to find a cure for this lethal genetic disease and save the lives of thousands of people around the globe."
- check out the release